Do COVID-19 Antibodies Provide Long-Term Protection?

Sheeba F. Ansari, Mubeen Memon, Ratan Kumar, Sidra Memon, Muhammad Khizar Memon

1. Internal Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, PAK
2. Pulmonology, Liaquat University of Medical and Health Sciences, Jamshoro, PAK
3. Internal Medicine, Civil Hospital Khairpur, Khairpur, PAK
4. Internal Medicine, Jinnah Sindh Medical University, Karachi, PAK

Corresponding author: Sidra Memon, sidramemon311@gmail.com

Abstract

Introduction: Post severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, an immune response is generated among healthy, immunocompetent individuals with immunoglobulins (IgG and IgM) antibodies. IgM rises earlier than IgG, indicating a recent infection. However, a detailed analysis is required to assess long-term immune reactions induced by antibodies.

Method and Materials: The study was conducted at a tertiary care hospital in Pakistan from June 2020 to October 2020 where serum samples were collected from patients. The samples were obtained by phlebotomy for antibody testing. All the reactive patients were followed up after 60 days of initial testing.

Results: A total of 728 patients participated in the study, of which 79 (10.8%) were seropositive at baseline. Seventy-two (91.1%) participants came back for follow-up after 60 days (two months) and were included in the final analysis. Among the 72 participants, 35 (48.6%) exhibited symptoms of coronavirus disease 2019 (COVID-19) infection and 37 (51.4%) were asymptomatic. After 60 days, 37 (including 20 symptomatic and 17 asymptomatic) participants were still seropositive for SARS-CoV-2 enzyme-linked immunosorbent assay (ELISA) test. Mean change in percentage from seropositive to seronegative was more in asymptomatic compared to symptomatic patients (54.0% vs. 42.8%).

Conclusion: In this study, humoral immunity against SARS-CoV-2 is not long-lasting among individuals with mild signs and symptoms. Care should be taken while implicating that antibodies can provide long term protection against SARS-CoV-2. Further large-scale studies are needed.

Categories: Internal Medicine, Infectious Disease, Public Health
Keywords: coronavirus, antibodies, pandemic

Introduction

Nearly all immune-competent individuals will develop an immune response following severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Like infections with other pathogens, SARS-CoV-2 infection elicits development of IgM and IgG antibodies, which are the most useful for assessing antibody response [1]. An assay that tests for IgM antibodies may detect a more recent infection with SARS-CoV-2, but typically both immunoglobulins (IgM and IgG) rise early in SARS-CoV-2 infections. IgM levels do wane earlier than IgG, and thus assays that test IgM alone may not detect prior infection [2]. Data generated through serological studies can greatly aid in supplementing the results from qRT-PCR (real-time quantitative reverse transcription polymerase chain reaction), as well as contribute to sero-epidemiology, which has been shown to help in the design of virus elimination programs [3].

It is not yet known if antibodies serve as an indication of the presence or absence of protective or sustained immunity. Negative SARS-CoV-2 antibody results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Therefore, results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status [4]. In a recent study, the presence of anti-SARS-CoV-2 antibodies neither indicated the rapid eradication of the virus nor provided immune protection from disease deterioration [5]. Moreover, a few recovered patients that were discharged from hospitals tested positive in nucleic acid tests, it is still necessary to develop new sensitive and specific detection methods for the confirmation of virus-infected persons, carriers, and recovered patients [6].

In an ongoing pandemic with so much uncertainty about the virus and disease itself, there are many more discoveries yet to be known. Further studies on coronavirus disease 2019 (COVID-19) antibodies or serology need to support whether they are protective in long-term or not.

Materials And Methods

How to cite this article
Ansari S F, Memon M, Kumar R, et al. (January 03, 2021) Do COVID-19 Antibodies Provide Long-Term Protection?. Cureus 13(1): e12441. DOI 10.7759/cureus.12441
This longitudinal study was conducted at the outpatient department (OPD) of the Internal Medicine department at a tertiary care hospital in Pakistan from June 2020 to October 2020. Participants were enrolled from June 2020 until August 2020 via convenient consecutive sampling. Informed consent was also taken. Liaquat University of Medical and Health Sciences issued approval LUMHS/2020/R-CV-IRB-04.

Serum samples were collected from patients for anti-SARS-CoV-2 antibodies. The samples were tested using ELISA against the SARS-CoV-2 spike protein’s prefusion-stabilized extracellular domain [7]. A signal to threshold ratio of around 1:100 serum dilution with background correction of greater than 1.0 was considered reactive, however, higher antibody titers were demonstrated with higher ratios. This demonstrated that the assay was 99.8% specific and 100% sensitive [8].

Those who were seropositive were asked to come back after 60 days for follow up in September and October 2020. They completed a survey for symptoms of viral illness (fever, shortness of breath, cough, sore throat, fatigue, and loss of smell) experienced in previous two months. Phlebotomy for serology was repeated.

We evaluated the change in the participants from seropositive to seronegative in 60 days. Data was analyzed using Statistical Package for Social Sciences (SPSS) version 23 (IBM Corp., Armonk, NY, USA).

## Results

After informed consent, 728 participants were enrolled in the study. Mean age of participants was 42 ± 17 years. There were 421 (57.8%) males and 307 (42.2%) females. Seventy-nine (10.8%) participants were seropositive at baseline. Seventy-two (91.1%) participants returned for follow-up after 60 days (two months) and were included in the final analysis. Among 72 participants, 35 (48.6%) were symptomatic and 37 (51.4%) were asymptomatic. After 60 days, 37 (51.3%) participants were seropositive for the SARS-CoV-2 ELISA test. Among symptomatic participants, out of 35 participants, 20 (54.1%) participants remained seropositive. Among asymptomatic participants, out of 37 participants, 17 (45.9%) participants remained seropositive. Mean change in percentage from seropositive to seronegative was more in asymptomatic compared to symptomatic patients (54.0% vs. 42.8%) (Table 1).

| Viral Symptoms | SARS-CoV-2 ELISA result |  |  |  |
|----------------|-------------------------|---|---|---|
|                | Reactive at Baseline    | Reactive at 60 days | Mean change in percentage from seropositive to seronegative |
| Symptomatic    | 35 (48.6%)              | 20 (54.1%)           | - 42.8%          |
| Asymptomatic   | 37 (51.4%)              | 17 (45.9%)           | - 54.0%          |

**TABLE 1: Comparison of sero-positivity at baseline and at day 60**

ELISA: enzyme-linked immunosorbent assay

## Discussion

SARS-CoV-2, a coronavirus, presents with signs and symptoms depending on the organ system involved. Respiratory system symptoms, high-grade fever, sore throat, nonproductive cough, shortness of breathing, diarrhea, and fatigue are often initial presenting complaints with neurological involvement or patients being asymptomatic also common. Air droplets or direct contact remains the common mode of transmission [9].

With a mean incubation period of 5.1 days, 97.5 percent of the patients develop symptoms from SARS-CoV-2 infection within 11.5 days, implying that a quarantine period of 14 days is required in suspected cases to potentially expose the infection [10]. Nucleic acid amplification diagnostic testing or real-time PCR of samples collected from suspected patient’s nasal and pharyngeal swabs or sputum remains the gold standard for diagnosis as recommended by World Health Organization (WHO) [11]. Serologic studies using ELISA are often also used as a screening test for SARS-CoV-2 infection, which however have not been proven to be solely used to diagnose or exclude the infection or to inform infection status [4,5].

The present study was conducted to see whether antibodies against COVID-19 or its serology are protective in the long term or not. It concluded that out of 72 participants who were included in the study and were seropositive at baseline, 37 (51.3%) remained seropositive after 60 days with almost equally (48.6%) becoming seronegative, which indicates that there might be a chance of no long-term protection from SARS-CoV-2 infection. Sero-negativity after 60 days was more commonly (54% vs 42.8%) seen in individuals who were asymptomatic as compared to individuals who were symptomatic at presentation. In their study to assess the duration of antibody response to SARS-CoV-2 infection in health care personnel, Patel et al. concluded that eight (42%) out of 19 seropositive individuals at baseline remained seropositive after 60 days while 11 (58%) became seronegative. Of these 11 who became seronegative, six (55%) were asymptomatic at presentation while only two (25%) were asymptomatic in individuals who remained seropositive, indicating
high seroconversion in asymptomatic individuals [12].

Antibody decay was found to be quicker after SARS-CoV-2 infection than that reported for SARS-CoV-1 [13,14]. Long et al. in their study to assess the immunological response of asymptomatic individuals infected with SARS-CoV-2 concluded that asymptomatic individuals had a weaker immune response due to long duration of viral shedding, significantly lower virus-specific IgG levels in the acute phase, and greater reduction in the IgG and neutralizing antibodies during the early convalescent phase of which 40% became seronegative during the same phase [14].

These findings indicate that humoral immunity against SARS-CoV-2 may not be long-lasting among individuals with mild illness, who compose the majority of cases with COVID-19 [13]. Also, serology tests cannot be solely used to diagnose or exclude the infection or to inform infection status.

Conclusions

In this study, almost half of the patients became seronegative for SARS-CoV-2 after two months. Mean change in percentage from seropositive to seronegative was greater in asymptomatic compared to symptomatic patients. Our study suggests that presence of immunoglobulins in the serum do not provide long-lasting immunity and there might be a chance of reinfection. Based on this result, we suggests patients who have recovered from COVID-19 should continue precautionary measures.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. Liaquat University of Medical and Health Sciences issued approval LUMHS/2020/R-CV-IRB-04. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Interim Guidelines for COVID-19 Antibody Testing. (2020). https://www.cdc.gov/coronavirus/2019-ncov/lab/antibody-tests-guidelines.html.
2. Frequently Asked Questions About Coronavirus (COVID-19) for Laboratories (Serology). (2020). https://www.cdc.gov/coronavirus/2019-ncov/lab/faq.html.
3. Lee CY, Lin RP, Renia L, Ng LF: Serological approaches for COVID-19: epidemiologic perspective on surveillance and control. Front Immunol. 2020, 11:879. 10.3389/fimmu.2020.00879
4. Beavis KG, Matushek SM, Abeleda AF, et al.: Evaluation of the EUROMMUN anti-SARS-CoV-2 ELISA assay for detection of IgA and IgG antibodies. J Clin Virol. 2020, 129:104468. 10.1016/j.jcv.2020.104468
5. Wu JL, Tseng WP, Lin CH, et al.: Four point-of-care lateral flow immunoassays for diagnosis of COVID-19 and for assessing dynamics of antibody responses to SARS-CoV-2. J Infect. 2020, 81:435-442. 10.1016/j.jinf.2020.06.023
6. Li C, Ren L: Recent progress on the diagnosis of 2019 novel coronavirus. Transbound Emerg Dis. 2020, 67:1485-1491. 10.1111/tbed.15620
7. Stubblefield WB, Talbot HK, Feldstein L, et al.: Seroprevalence of SARS-CoV-2 Among Frontline Healthcare Personnel During the First Month of Caring for COVID-19 Patients - Nashville, Tennessee [published online ahead of print, 2020 Jul 6]. Clin Infect Dis. 2020, 956. 10.1093/cid/iaaa956
8. Roche’s COVID-19 Antibody Test Receives FDA Emergency Use Authorization and Is Available in Markets Accepting the CE Mark. (2020). https://www.roche.com/media/releases/med-cor-2020-05-05.htm.
9. Rothan HA, Byrareddy SN: The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020, 109:102435. 10.1016/j.jaut.2020.102435
10. Lauer SA, Grantz KH, Bi Q, et al.: The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020, 172:577-582. 10.7326/m20-0504
11. Ahn DG, Shin HJ, Kim MH, et al.: Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol. 2020, 30:515-324. 10.4041/jmb.2003.05011
12. Patel MM, Thornburg NJ, Stubblefield WB, Keipp Talbot H, Coughlin MM, Feldstein L, Self WH: Change in antibodies to SARS-CoV-2 over 60 days among health care personnel in Nashville, Tennessee. JAMA. 2020, 324:1781-1782. 10.1001/jama.2020.15796
13. Ibarroondo FJ, Falcher JA, Goodman-Meza D, et al.: Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. 2020, 383:1085-1087. 10.1056/NEJMoa2025179
14. Long QX, Tang XJ, Shi QL, et al.: Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020, 26:1200-1204. 10.1038/s41591-020-0965-6